Complix

Technologiepark 94
9052 Zwijnaarde
BE
Complix
Foundation date
23/06/2008
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Cardiovascular
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
- #Neoplasms / cancer / oncology
Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.
Upcoming events
All events-
0310 '23
-
1810 '23
EMDS2023@VIB
Event by: VIB -
1212 '23
BioFIT 2023
Event by: Eurasanté
Latest news
More news-
argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis
Thursday September 21st 2023
Read more
-
Galapagos appoints Simon Sturge to its Board of Directors
Tuesday September 19th 2023
Read more
-
13th Investment for HERAN Partners: Broken String Biosciences (UK)
Tuesday September 19th 2023
Read more
Jobs
More jobs-
-
-
23/09/23
East Flanders
ERC-funded postdoc position on inter-organelle communication during plant biotic stress responses
Permanent
VIB